Detail
| LncRNA Name | FAL1 |
| Synonyms | FALEC, FAL1, LINC00568, ncRNA-a1 |
| Region | GRCh38_1:150515757-150518032 Sequence |
| Ensembl | ENSG00000228126 |
| RefSeq | NR_051960 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | osteosarcoma |
| ICD-0-3 | M8260/3 |
| Methods | qRT-PCR, Western blot analysis |
| Sample | Human osteosarcoma cell lines (U2OS, HOS, SAOSâ??2, 143B, and SW1353 cells from female patients and MGâ??63 cells from a male patient) and human osteoblast cell lines (hFOB1.19 and NHOst), The osteosarcoma specimens and matched nontumor tissues, osteosarcoma blood samples |
| Expression Pattern | up-regulated |
| Function Description | FAL1 expression was significantly upregulated in human osteosarcoma tissues and cell lines compared with their normal controls. FAL1 expression level was positively correlated with the distance metastasis (P?=?.008) and tumor stage ( P?=?.013).our study showed that lncRNA FAL1 exhibits an important pro-oncogenic effect on osteosarcoma progression by targeting EMT, which may serve as a potential therapeutic target for osteosarcoma. |
| Pubmed ID | 29987852 |
| Year | 2018 |
| Title | LncRNA FAL1 is a negative prognostic biomarker and exhibits pro-oncogenic function in osteosarcoma. |
| External Links |
| Links for FAL1 | GenBank HGNC lncrnadb Noncode |
| Links for osteosarcoma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.